UNSPSC 51144005: Clominorex

This classification denotes an anorexiant with the molecular formula C9H9ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) O1R2462WA0, chemically known as 5-(4-chlorophenyl)-1,3-oxazolidin-2-imine but more generally known as clominorex, which bears US NIH Compound Identifier 19752. European Medicines Agency schedules Clominorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06724MIG. The term CLOMINOREX is an International Non-Proprietary Name.

UNSPSC 51144005 Clominorex is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone, over-the-counter items, generic multi-source medications, and related drug-management systems for community health, public-health emergency response, and benefit programs. Recent solicitations show the code spans both direct product procurement through competitive bidding and cooperative purchasing arrangements that aggregate demand across multiple state and local participants. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances; Seminole County, Florida, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear as active recent buyers. Work solicited includes annual supply contracts with quarterly delivery cycles, direct-to-manufacturer prescription programs designed to bypass traditional pharmacy benefit managers and group purchasing organizations, and multi-state cooperative agreements for generic pharmaceuticals distributed through authorized wholesalers.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida, issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline, requiring electronic bid submission and quarterly delivery to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting models outside traditional pharmacy benefit manager arrangements. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026; evaluation weighting emphasizes price competitiveness at 75 percent and includes administrative fee compliance and electronic data interchange capability requirements.